scholarly journals Erratum: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Jianlin Xu ◽  
Haitang Yang ◽  
Bo Jin ◽  
Yuqing Lou ◽  
Yanwei Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy ◽  
Egfr Tyrosine Kinase Inhibitors

scholarly journals EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Jianlin Xu ◽  
Haitang Yang ◽  
Bo Jin ◽  
Yuqing Lou ◽  
Yanwei Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Egfr Tyrosine Kinase Inhibitors ◽  
L858r Mutation

Abstract The efficacy of EGFR tyrosine kinase inhibitors (TKIs) varies among different EGFR mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non-small cell lung cancer (NSCLC) patients with the L858R mutation. The progression-free survival (PFS) for patients receiving TKIs as first-line therapy was longer than those who received chemotherapy (hazard ratio [HR]: 0.44, P < 0.001). Subgroup analyses showed that first-line TKI therapy resulted in longer PFS among non-smokers (HR: 0.41, P < 0.001), male (HR: 0.49, P = 0.002), female (HR: 0.39, P < 0.001), and patients with adenocarcinoma histology (HR: 0.41, P < 0.001). However, among patients with non-adenocarcinoma histology (HR: 1.11, P = 0.824) and those who used to smoke (HR: 0.55, P = 0.093), first-line TKI therapy failed to demonstrate statistically longer PFS compared to chemotherapy. Our results demonstrated that for patients with L858R mutation, first-line TKI therapy provided better survival benefits. However, among non-adenocarcinoma patients and those who used to smoke, the PFS in cohorts receiving first-line chemotherapy or TKI were not significantly different. The results of the current study will be helpful for decision-making in the treatment of patients with L858R mutation.

Outcome of Surgical Resection as a First Line Therapy in T3 Non-small Cell Lung Cancer Patients

2013 ◽  
Vol 37 (11) ◽  
pp. 2574-2580 ◽  
Author(s):  
Tomoyoshi Takenaka ◽  
Masakazu Katsura ◽  
Yasunori Shikada ◽  
Sadanori Takeo
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy

Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients

2016 ◽  
Vol 5 (S7) ◽  
pp. S1443-S1448
Author(s):  
Luis E. Raez ◽  
Christian Rolfo ◽  
Mauricio Mahave ◽  
Christian Caglevic
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Lung Cancer Patients ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document